Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-Year experience in Victoria, Australia

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 98, Issue 1, 2013, Pages

  Cheong, Jeanie Ling ^a,b,c   Anderson, Peter ^b,c   Roberts, Gehan ^b,d   Duff, Julianne ^a   Doyle, Lex W ^b,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTICLE; AUSTRALIA; CEREBRAL PALSY; COHORT ANALYSIS; DISEASE SEVERITY; EXTREMELY LOW BIRTH WEIGHT; EXTREMELY PRETERM; FEMALE; HUMAN; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NERVE CELL DIFFERENTIATION; NEWBORN; NEWBORN DISEASE; NEWBORN MORTALITY; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADRENAL CORTEX HORMONES; BRONCHOPULMONARY DYSPLASIA; FEMALE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; MALE; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY OUTCOME; VICTORIA;

EID: 84871616646     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fetalneonatal-2011-301355     Document Type: Article

References (24)

1. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2010;1:CD001146.
2. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009;1:CD001146.
3. AAP. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-8.
4. Hintz SR, Kendrick DE, Wilson-Costello DE, et al.; NICHD Neonatal Research Network. Early-childhood neurodevelopmental outcomes are not improving for infants born at <25 weeks' gestational age. Pediatrics 2011;127:62-70.
5. Shinwell ES, Lerner-Geva L, Lusky A, et al. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007;92:F30-3. (Pubitemid 46132963)
6. Yoder BA, Harrison M, Clark RH. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009;124:673-9.
7. Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006;118: e1328-35. (Pubitemid 46393637)
8. Wilson-Costello D, Friedman H, Minich N, et al. Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000-2002. Pediatrics 2007;119:37 -45.
9. Bode MM, D'Eugenio DB, Forsyth N, et al. Outcome of extreme prematurity: a prospective comparison of 2 regional cohorts born 20 years apart. Pediatrics 2009;124:866-74.
10. Kobaly K, Schluchter M, Minich N, et al. Outcomes of extremely low birth weight (<1 kg) and extremely low gestational age (<28 weeks) infants with bronchopulmonary dysplasia: effects of practice changes in 2000 to 2003. Pediatrics 2008;121:73-81.
11. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:217-24.
12. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:111-7.
13. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005;115:655 -61.
14. Wilson-Costello D, Walsh MC, Langer JC, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009;123:e430-7.
15. Doyle LW; Victorian Infant Collaborative Study Group. Evaluation of neonatal intensive care for extremely low birth weight infants in Victoria over two decades: I. Effectiveness. Pediatrics 2004;113:505-9.
16. Doyle LW, Roberts G, Anderson PJ. Outcomes at age 2 years of infants < 28 weeks ' gestational age born in Victoria in 2005. J Pediatr 2010;156:49-53.e1.
17. Doyle LW, Kitchen WH, Lumley J, et al. Accuracy of mortality rates for livebirths 500-999 g birthweight. Med J Aust 1992;156:72.
18. Kitchen WH, Doyle LW, Ford GW, et al. Changing two-year outcome of infants weighing 500 to 999 grams at birth: a hospital study. J Pediatr 1991;118:938-43.
19. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214-23. (Pubitemid 27226331)
20. Bayley N. Bayley Scales of Infant Development. New York: The Psychological Corporation 1969.
21. Bayley N. The Bayley Scales of Infant Development - Revised . New York: Psychological Corporation 1993.
22. Bayley N. The Bayley Scales of Infant Development. Third Edition. New York: Psychological Corporation 2005.
23. Doyle LW, Davis PG, Morley CJ, et al.; DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006;117:75-83. (Pubitemid 46050522)
24. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989;320:1505-10. (Pubitemid 19145801)